Open Access<p>PRDX1 is a Tumor Suppressor for Nasopharyngeal Carcinoma by Inhibiting PI3K/AKT/TRAF1 Signaling</p>
Author(s) -
Hang Xiao,
Taoyu Yang,
Lilong Yan,
Jing Feng,
Boyen Huang,
Yu Jiang
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s252286
Subject(s) - nasopharyngeal carcinoma , cancer research , protein kinase b , gene knockdown , pi3k/akt/mtor pathway , epithelial–mesenchymal transition , carcinogenesis , medicine , signal transduction , cell growth , metastasis , biology , cell culture , cancer , microbiology and biotechnology , radiation therapy , genetics
Peroxiredoxin 1 (PRDX1) has been identified as a dual regulator of tumorigenesis. However, its expression, clinical significance, and biological function in nasopharyngeal carcinoma (NPC) remain unknown. This study aimed to explore the role and underlying mechanisms of PRDX1 in NPC.